BIO was as busy as ever in Boston this year. With more to come soon, here are a few initial thoughts on three events I ...

GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine ...

A “heavy workload” and “limited resources” have left the agency unable to meet a June 17 deadline to approve a therapy ...

According to an internal email, the agency may be in for more consolidation in areas including human resources, ...

NUCALA powder for solution for injection 100 mg Nombre local: NUCALA Powder for solution for injection 100 mg País: Lituania Laboratorio: GlaxoSmithKline Trading Services Limited Vía: Vía subcutanea ...

GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for the continued development and distribution.

The FDA may be facing a 4% cut to its overall budget courtesy of the Trump administration, but that hasn’t stopped the agency from unveiling a new generative AI tool a month ahead of schedule ...

Investing.com -- Berenberg has lowered its rating on GSK plc (LON:GSK) to Hold from Buy, a move driven by the stock’s strong year-to-date (YTD) performance and an expected pause in investor ...

“We move to a Hold rating (from Buy) and reiterate our price target of GBP16.00,” the analysts led by Kerry Holford wrote. While GSK’s valuation remains undemanding, the analysts “prefer Sanofi ...

Treatment with Nucala, an interleukin-5 antagonist monoclonal antibody, significantly reduced exacerbations leading to hospitalizations and emergency department visits. The Food and Drug ...

FDA approves Nucala as add-on therapy for certain COPD patients May 23, 2025; My smile hid symptoms of depression associated with COPD May 13, 2025; Lessons from my pet robin on living with COPD May 6 ...

Nucala offers doctors a new, powerful, and targeted treatment that can truly help bridge the health equity gaps for Black Americans living with uncontrolled eosinophilic COPD. But for this benefit to ...